In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), 63% either preferred the biosimilar or had no preference for either, 87% had no concerns about losing disease control due to switching, and 49% reported adequate knowledge about the safety and efficacy of the biosimilar. The authors called for future research to “assess means to educate effectively patients on biosimilars’ safety and efficacy.”
Image credit: anton - stock.adobe.com
Adalimumab is a monoclonal antibody to tumor necrosis factor (TNF)-α used to treat a variety of immune-mediated inflammatory diseases, such as rheumatoid arthritis. Amjevita was the first adalimumab biosimilar to enter the US market in January 2023. The reference product is available in citrate-containing and citrate-free formulations, the latter of which was developed to reduce injection site pain. Amjevita is available only as a citrate-free formulation.
The authors wrote that although a 2018 meta-analysis of 8 randomized controlled trials concluded are were no significant differences in safety and efficacy between adalimumab biosimilars and the reference product in rheumatoid arthritis (RA), no studies had assessed treatment satisfaction and product preference following a switch to adalimumab-atto in US patients with inflammatory arthritis.
The investigators conducted a telephone survey of adult patients with RA, ankylosing spondylitis, or psoriatic arthritis in Kaiser Permanente’s Southern California and Colorado regions who had recently switched from the originator to Amjevita. Of 1128 eligible patients, 243 patients completed the survey.
The questionnaire asked patients about their product preference, their concerns about biosimilar therapy, and any observed differences between the reference product and biosimilar.
Prior to switching, patients had been treated with the reference product for a median of 4.0 years. About 28% of patients reported preferring the biosimilar over the reference product, and 35% had no preference for either product.
Most patients (87%) reported having no concerns with losing control over their disease by switching from the reference product to the biosimilar. Almost half (45%) of patients who had previously been treated with the citrate-containing formulation of the reference adalimumab reported no differences immediately after injection of the biosimilar, and of those who did report a difference, most (92%) reported the biosimilar was more favorable regarding injection-site pain and discomfort.
Of those who had previously received the citrate-free formulation of the reference product, just over half (52.5%) reported no differences immediately after injection of the biosimilar. Most (80%) of those who did report a difference rated the reference product as more favorable. About half (49%) of patients felt they knew enough regarding the safety and efficacy of the biosimilar.
Most patients (90%) reported no concerns with the cost of the biosimilar. The authors concluded that Amjevita was overall “well received” by patients with autoimmune arthritis who switched from the reference product, but that future research should assess educating patients effectively prior to a switch from a reference product to a biosimilar.
Reference
Pham C, Niu F, Hui RL, Le KN, Delate T. Patient perceptions on switching from reference product adalimumab to biosimilar adalimumab-atto. Clin Rheumatol. 2024;43(3):1269-1270. doi:10.1007/s10067-023-06822-2.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.
Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
June 2nd 2024On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars, as well as the feasibility of switching to them.
Eye on Pharma: EU Biosimilar Approval, Launches and Product Returns, Denosumab Switching Data
July 10th 2024The European Union approves a tocilizumab biosimilar and the US sees another launch, Genentech’s ophthalmology biobetter returns to the market, and Samsung Bioepis shares data on switching to its denosumab biosimilar.